SciBase’s Interim Report for Q2 2026 Highlights Strong Sales Growth and Expanding Market Opportunities

Overview

SciBase recently released its interim report detailing the company's performance from January to June 2026, with the second quarter numbers showcasing remarkable growth in various aspects of the business.

Financial Highlights

For the second quarter, SciBase reported net sales of TSEK 15,308, a staggering increase of 74% compared to the same period last year (TSEK 8,791); when accounting for currency fluctuations, the growth surge was even more pronounced at 84%. Despite the rise in sales, the company also faced challenges, posting a loss after tax totaling TSEK 28,893 (from TSEK 22,911). Consequently, the loss per share improved to SEK 2.83 from SEK 6.77.

The gross margin, however, faced a decline to 52.6% from 66.2%, driven by several factors, including adverse currency development and increased production costs. Moreover, the company experienced a negative cash flow from operations, amounting to TSEK 33,095 compared to TSEK 20,466 in the prior quarter. Despite these challenges, electrode sales volumes saw significant growth of 118%, totaling 40,144 units, a substantial increase from 18,398 units.

Strategic Developments

SciBase emphasized its commitment to advancing its skin cancer detection technology during the first half of the year. Their collaboration with Castle Biosciences enters a critical stage with new clinical studies focusing on atopic dermatitis flare prediction, demonstrating SciBase's capability in utilizing its Nevisense technology for innovative healthcare solutions.

Germany's skin cancer market contributed positively with an 18% increase in sales, while the U.S. market for skin cancer detection soared by 80%. Notably, revenue from the skin barrier products skyrocketed by an impressive 3,231%. Additionally, SciBase has made a strategic decision to perform a reverse split of its shares (1:1100) to enhance market visibility and shareholder value.

The research landscape around Nevisense further expanded, supported by peer-reviewed publications showcasing its effectiveness in identifying atopic dermatitis in newborns and its ability to detect skin barrier damage from household cleaning products.

Looking Ahead

The company also submitted a 510(k) premarket notification to the U.S. FDA, aiming to expand Nevisense's indications to include assessment for non-melanoma skin cancers. This step represents a pivotal move to penetrate a larger segment of the skin cancer market, potentially driving further growth in 2026.

Conclusion

In conclusion, SciBase's second-quarter report reflects both triumphs and challenges. The substantial increase in sales, particularly in electrode units, showcases the company’s potential for growth despite ongoing losses. With proactive steps towards regulatory approvals and strategic collaborations, SciBase is positioned to enhance its influence in the dermatological field and shows promise for sustained success in future quarters.